Samsung Enters Oncology as Trastuzumab Accepted For EU Review
Executive Summary
Samsung Bioepis's trastuzumab has become the South Korean company’s fifth biosimilar candidate to be filed for approval in Europe and also marks its planned entry into the oncology sector in the region.
You may also be interested in...
Samsung Looks Beyond Biosimilars Via Takeda Tie-Up
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.
2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma
For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.
Biocon Confident As First Biosimilars Seen Hitting Europe In Early 2018
India’s leading biologics company Biocon has said it expects its first biosimilar products to be launched in the European market by early 2018 and is bullish on both its plans in the sector and earnings prospects after reporting quarterly net profit soared by a better than expected 52%.